Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/3TC switch versus tenofovir-containing triple therapy in virologically suppressed women with HIV-1
2021-002565-17Phase 3Active
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dolutegravir, lamivudine, tenofovir alafenamide and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Virologic suppression at week 48. Started Oct 2021; status: active.
02
Drugs
dolutegravirlamivudinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2021-002565-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002565-17.